blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2965752

EP2965752 - PHARMACEUTICAL FORMULATION COMPRISING EZETIMIBE [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  16.02.2018
Database last updated on 06.11.2024
FormerRequest for examination was made
Status updated on  16.12.2016
Most recent event   Tooltip19.10.2024New entry: Reply to examination report 
Applicant(s)For all designated states
ratiopharm GmbH
Graf-Arco-Strasse 3
89079 Ulm / DE
[2016/02]
Inventor(s)01 / GIRIDHARA RAO, Pasupuleti
S/o P. Somasekhara rao 27/1/233
Balaji nagar
524 002 Nellore / IN
02 / HUSSAIN, Javed
Hussain Villa, Plot No. 8, N-8
Sector C-3, Cidco, Azad Chowk
431003 Aurangabad, Maharashtra / IN
03 / GAT, Ganesh V.
61/5 United Western CHS
Godavari Bunglow
Karvenagar
411052 Pune, Maharashtra / IN
 [2016/02]
Representative(s)Kraus & Lederer PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
[N/P]
Former [2016/02]Best, Michael
Lederer & Keller
Patentanwälte Partnerschaft mbB
Unsöldstrasse 2
80538 München / DE
Application number, filing date15171262.709.12.2008
[2016/02]
Priority number, dateIN2007DEL257910.12.2007         Original published format: IN DE25792007
[2016/02]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2965752
Date:13.01.2016
Language:EN
[2016/02]
Search report(s)(Supplementary) European search report - dispatched on:EP11.12.2015
ClassificationIPC:A61K9/20, A61K31/397
[2016/02]
CPC:
A61K9/2018 (EP,US); A61K31/397 (EP,US); A61K9/2059 (EP,US);
A61K9/2095 (EP,US); A61P3/00 (EP); A61P3/06 (EP)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/34]
Former [2016/02]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:PHARMAZEUTISCHE FORMULIERUNG ENTHALTEND EZETIMIB[2016/02]
English:PHARMACEUTICAL FORMULATION COMPRISING EZETIMIBE[2016/02]
French:COMPOSITION PHARMACEUTIQUE COMPRENANT L'EZETIMIBE[2016/02]
Examination procedure13.07.2016Amendment by applicant (claims and/or description)
13.07.2016Examination requested  [2016/34]
15.02.2018Despatch of a communication from the examining division (Time limit: M12)
14.02.2019Reply to a communication from the examining division
16.07.2020Despatch of a communication from the examining division (Time limit: M06)
25.01.2021Reply to a communication from the examining division
21.03.2023Despatch of a communication from the examining division (Time limit: M04)
19.06.2023Observations by third parties
21.07.2023Reply to a communication from the examining division
28.06.2024Despatch of a communication from the examining division (Time limit: M04)
17.10.2024Reply to a communication from the examining division
Parent application(s)   TooltipEP08859677.0  / EP2217214
Fees paidRenewal fee
09.06.2015Renewal fee patent year 03
09.06.2015Renewal fee patent year 04
09.06.2015Renewal fee patent year 05
09.06.2015Renewal fee patent year 06
09.06.2015Renewal fee patent year 07
22.12.2015Renewal fee patent year 08
23.12.2016Renewal fee patent year 09
21.12.2017Renewal fee patent year 10
19.12.2018Renewal fee patent year 11
23.12.2019Renewal fee patent year 12
24.12.2020Renewal fee patent year 13
24.12.2021Renewal fee patent year 14
29.12.2022Renewal fee patent year 15
19.12.2023Renewal fee patent year 16
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[YD]WO9508532  (SCHERING CORP [US], et al);
 [Y]WO2006060808  (TEVA PHARMA [IL], et al);
 [XY]WO2007103453  (TEVA PHARMA [IL], et al);
 [XY]US2007275052  (MAHAJAN ABHAY [IN], et al);
 [YP]WO2008032338  (SATYANARAYANA REDDY MANNE [IN], et al);
 [E]WO2009077573  (KRKA TOVARNA ZDRAVIL D D NOVO [SI], et al);
by applicantWO9508532
 WO9535277
 WO2006060808
 EP1353696
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.